RAPP FY 2024 Earnings — Rapport Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

RAPPRapport Therapeutics, Inc. Common Stock

$1B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$839,000

Operating Income

-$83M

Net Income

-$78M

EPS (Diluted)

$-0.38

Cash Flow

Operating Cash Flow

-$65M

Free Cash Flow

-$67M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$315M

Total Liabilities

$10M

Stockholders' Equity

$305M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$839,000	-$112,000	-649.1%
Operating Income	-$83M	-$36M	-129.6%
Net Income	-$78M	-$35M	-125.1%